Chronic Lymphocytic Leukemia Research

Chronic lymphocytic leukemia (CLL) is a malignancy of mature B-cells whose clinical behavior is shaped heavily by the genetic landscape of the tumor, including deletions, chromosomal rearrangements, and point mutations such as those affecting TP53. Understanding these genomic aberrations has become central to predicting how a patient's disease will progress and to selecting therapies—particularly BTK inhibitors like ibrutinib and the monoclonal antibody rituximab—that can be tailored to molecular subgroups. A pressing open question is why some patients develop resistance to BTK inhibition and how acquired mutations drive that resistance, which has motivated research into combination strategies and next-generation targeted agents. Closely related conditions such as Waldenström macroglobulinemia share overlapping genetic features with CLL, making cross-disease comparisons a productive avenue for identifying shared therapeutic vulnerabilities.

Works

99,370

Total citations

1,198,886

Keywords

Chronic Lymphocytic LeukemiaGenomic AberrationsBTK InhibitorsRituximabIbrutinibPrognostic Factors